行情

CATB

CATB

Catabasis Pharms
NASDAQ

实时行情|Nasdaq Last Sale

4.800
-0.100
-2.04%
交易中 15:10 10/15 EDT
开盘
4.900
昨收
4.900
最高
5.22
最低
4.765
成交量
18.79万
成交额
--
52周最高
9.76
52周最低
3.600
市值
5,576.21万
市盈率(TTM)
-1.6600
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CATB 新闻

  • 高盛CEO:Apple Card是"有史以来最成功信用卡发行"
  • 新浪美股.25分钟前
  • 联储贴现率决策内部分歧加剧 对立双方接近"五五开"
  • 新浪美股.28分钟前
  • 巴菲特向美联储寻求批准 将增持美国银行股份超过10%
  • 新浪美股.38分钟前
  • 邓普顿基金明星经理失手 旗舰债基三个月亏30亿美元
  • 新浪美股.53分钟前

更多

所属板块

生物技术和医学研究
+1.94%
制药与医学研究
+1.27%

热门股票

名称
价格
涨跌幅

CATB 简况

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
展开

Webull提供Catabasis Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。